MarketInOut Stock Screener Log In | Sign Up

Actuate Therapeutics Inc

IEX • Healthcare • Biotechnology • Quote as of 10/27/2026 15:59
Actuate Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization9.61 mln
Float10.23 mln
Earnings Date11/13/2026

Piotroski F-Score

4 / 9
Borderline

Relative Strength

11 / 100
Significantly lagging

Debt / Equity

0.41
Low leverage

ROE

-487
Deeply negative

ROA

-194
Deeply negative

Business Description

Actuate Therapeutics is a Fort Worth, Texas-based company focused on developing new cancer treatments. Its main drug, elraglusib, is currently being tested in clinical trials for several difficult-to-treat cancers, including advanced pancreatic cancer and certain childhood cancers such as Ewing sarcoma, neuroblastoma, and pediatric leukemias. The company was founded in 2015 and has been building its research pipeline with the goal of bringing more effective options to patients with limited treatment choices.

Key Fundamentals

EPS-0.87
ROE-487
ROIC-1,711
ROA-194
Interest Cover-1,026
EBITDA, mln-20.43
EV / EBITDA-0.74
EV / EBIT-0.74

Quote Details

Last 0.3995
Change -0.1205 (-23.17%)
Open 0.3793
Volume 1,670,078
Turnover 667,196
Average Volume 418,414

Financial Ratios

Leverage Ratio5.26
Current Ratio1.25
Price / Book20.25
Price / Tangible Book20.25
Debt / Equity0.41

Financial Strength

Piotroski F-Score 4 / 9
Short Ratio4.60
Short % of Float12.59

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -34.4% 0 / 100   
1 Month -44.36% 2 / 100   
2 Months -68.29% 2 / 100   
6 Months -86.27% 1 / 100   
1 Year -94.4% 2 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog